Understand the source comparison
GHRP-2 Versus GHRP-6, Hexarelin, and Ipamorelin: Mechanistic Differences in Ghrelin Receptor Agonism
All growth hormone-releasing peptides share structural homology and bind to GHS-R1a, but GHRP-2 acetate ghrelin receptor agonism has a distinct profile compared to related secretagogues. GHRP-6, the predecessor to GHRP-2, demonstrates similar GH-releasing pote
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- All growth hormone-releasing peptides share structural homology and bind to GHS-R1a, but GHRP-2 acetate ghrelin receptor agonism has a distinct profile compared to related secretagogues. GHRP-6, the predecessor to GHRP-2, demonstrates similar GH-releasing potency but with significant off-target effects: GHRP-6 binds to CD36 scavenger receptors, stimulating ghrelin-like appetite signaling and producing marked hyperphagia in animal models. GHRP-2 was specifically designed to minimize CD36 interaction while preserving GHS-R1a affinity. The result is comparable GH release with reduced orexigenic side effects. Quantitatively, GHRP-6 and GHRP-2 produce near-identical peak GH levels at equimolar doses, but GHRP-6 causes dose-dependent increases in food intake that GHRP-2 does not replicate.
- Hexarelin, another ghrelin receptor agonist, produces the highest GH release per microgram of any synthetic secretagogue. But it also demonstrates significant cardiac tropism. Hexarelin binds to CD36 receptors expressed on cardiomyocytes, producing measurable increases in cardiac contractility and left ventricular mass in animal models. This cardioprotective effect is desirable in some research contexts, but it represents an off-target mechanism absent from GHRP-2 acetate ghrelin receptor agonism. For researchers focused exclusively on GH axis modulation without cardiovascular confounds, GHRP-2 offers cleaner pharmacology.
- Ipamorelin, conversely, is the most selective GHS-R1a agonist in clinical use. It produces GH release comparable to GHRP-2 but with virtually no effect on prolactin or cortisol. Both of which are mildly elevated by GHRP-2 at higher doses. The trade-off is potency: ipamorelin requires approximately 30–50% higher doses than GHRP-2 to achieve equivalent peak GH levels. In research settings where minimizing off-target endocrine effects is paramount, ipamorelin is often preferred. Where maximal GH output per microgram of peptide is the priority, GHRP-2 acetate ghrelin receptor agonism delivers superior efficiency.
- Another critical distinction is cortisol and ACTH stimulation. GHRP-2 at doses above 1 mcg/kg produces measurable increases in ACTH (adrenocorticotropic hormone) and cortisol through hypothalamic CRH (corticotropin-releasing hormone) activation. This effect is dose-dependent and transient. Cortisol returns to baseline within 90–120 minutes. But it complicates interpretation in metabolic studies where cortisol itself has lipolytic and anti-anabolic effects. GHRP-6 produces similar cortisol elevation; ipamorelin does not. For multi-week research protocols, the cumulative impact of repeated cortisol spikes must be considered when selecting a secretagogue.